atopic dermatitis

EAACI biological guidelines – dupilumab for children and adults with moderate-to-severe atopic dermatitis

422. Agache, I.+, Akdis, C., Akdis, M., Brockow, K., Chivato, T., del Giacco, S., Eiwegger T., Eyerich, K. Giménez-Arnau, A., Gutermuth, J., Guttman-Yassky, E., Maurer, M., Ogg, G., Ong, P. Y., O’Mahony, L., Schwarze, J., Warner, A., Werfel, T., Palomares, O., and Jutel, M.: EAACI biological guidelines – dupilumab for children and adults with moderate-to-severe atopic dermatitis. Allergy 2021: 76; 988-1009. IF: 14.71

o.422

EAACI biological guidelines – dupilumab for children and adults with moderate-to-severe atopic dermatitis Read More »

Mas-related G protein-coupled receptor X2 and its activators in dermatologic allergies

164. Kühn, H., Kolkhir, P., Babina, M., Düll, M., Frischbutter, S., Fok, J. S., Jiao, Q., Metz, M., Scheffel, J., Wolf, K., Kremer, A. E., and Maurer, M.+: Mas-related G protein-coupled receptor X2 and its activators in dermatologic allergies. J. Allergy Clin. Immunol. 2021: 147; 456-469. IF: 14.29

r.164

Mas-related G protein-coupled receptor X2 and its activators in dermatologic allergies Read More »

Efficacy and safety of Dupilumab for moderate-to-severe atopic dermatitis: a systematic review for the EAACI biologicals guidelines

411. Agache, I.+, Song, Y., Posso, M., Alonso-Coello, P., Rocha, C., Solà, I., Beltran, J., Akdis, C., Akdis, M., Brockow, K., Chivato, T., del Giacco, S., Eiwegger, T., Eyerich, K., Giménez-Arnau, A., Gutermuth, J., Guttman-Yassky, E., Maurer, M., Ogg, G., Ong, P. Y., O’Mahony, L., Schwarze, J., Werfel, T., Canelo-Aybar, C.*, Palomares, O.*, and Jutel, M.*: Efficacy and safety of Dupilumab for moderate-to-severe atopic dermatitis: a systematic review for the EAACI biologicals guidelines. Allergy 2021: 76; 45-58. IF: 14.71

o.411

Efficacy and safety of Dupilumab for moderate-to-severe atopic dermatitis: a systematic review for the EAACI biologicals guidelines Read More »

Anti-pruritic effect of sertaconazole 2% cream in atopic dermatitis subjects: a prospective, randomized, double-blind, vehicle-controlled, multi-centre clinical trial of efficacy, safety and local tolerability

248 Ständer, S.+, Metz, M., Ramos, M. H., Maurer, M. Schoepke, N., Tsianakas, A., Zeidler, C., and Luger, T. A.: Anti-pruritic effect of sertaconazole 2% cream in atopic dermatitis subjects: a prospective, randomized, double-blind, vehicle-controlled, multi-centre clinical trial of efficacy, safety and local tolerability. Acta Derm. Venereol. 2016: 96; 792-796. IF: 3.65

Anti-pruritic effect of sertaconazole 2% cream in atopic dermatitis subjects: a prospective, randomized, double-blind, vehicle-controlled, multi-centre clinical trial of efficacy, safety and local tolerability Read More »

© 2024 Marcus Maurer